Condition
Non-familial Hypercholesterolemia
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
P 3 (1)
P 4 (2)
Trial Status
Unknown1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04885218Phase 3CompletedPrimary
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
NCT03694197Phase 4Terminated
Long Term Safety Study of PRALUENT
NCT00295373Phase 4UnknownPrimary
Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?
Showing all 3 trials